Rebecca Taub
Company: Madrigal Pharmaceuticals
Job title: Founder, Chief Executive & Medical Officer, President - Research & Development
Seminars:
Illuminating the Breakthrough Therapy Designation for Resmetirom & Outlining the Safety & Efficacy Results for Treating NASH 8:30 am
Leveraging the learnings of a multicentre, randomized, double-blind, placebo-controlled Phase 3 study How were non-invasive measures used? Comprehending the primary and secondary efficacy endpoints used to characterize the potential clinical benefits on cardiovascular endpointsRead more
day: Conference Day 1